Navigation Links
Endo Pharmaceuticals Announces Agreement to Acquire Qualitest Pharmaceuticals for $1.2 Billion
Date:9/28/2010

.30Costs related to the acquisition of Penwest Pharmaceuticals Co.

$0.22$0.22Costs related to the acquisition of Qualitest Pharmaceuticals

$0.02$0.02Interest expense adjustment for ASC 470-20 and the amortization of the premium on debt acquired from Indevus

$0.15$0.15Tax effect of pre-tax adjustments at the applicable tax rates and certain other expected cash tax savings as a result of the Indevus, HealthTronics, Penwest and Qualitest acquisitions

($0.44)($0.42)Diluted adjusted income per common share guidance $3.30To$3.35The company's guidance is being issued based on certain assumptions including:


  • Certain of the above amounts are based on estimates and there can be no assurance that Endo will achieve these results.
  • Includes all completed business development transactions as of September 28, 2010 and the acquisitions of Penwest Pharmaceuticals Co. and Qualitest Pharmaceuticals.
  • About EndoEndo Pharmaceuticals is a U.S.-based, specialty healthcare solutions company, focused on high-value branded products and specialty generics. Endo is redefining its position in the healthcare marketplace by anticipating and embracing the evolution of health decisions based on the need for high-quality and cost-effective care. We aim to be the premier partner to healthcare professionals and payment providers, delivering an innovative suite of complementary diagnostics, drugs, devices and clinical data to meet the needs of patients in areas such as pain, urology, oncology and endocrinology. For more information about Endo Pharmaceuticals, and its wholly owned subsidiary HealthTronics, Inc., please visit www.endo.com .

    Forward-Looking Statements This press release contains forward-looking statements regarding, among other things, the proposed business combination between Endo and Qualitest, Endo's and Qualitest's financial position, results of operation
    '/>"/>

    SOURCE Endo Pharmaceuticals
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related medicine technology :

    1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
    2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
    3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
    4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
    5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
    6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
    7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
    8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
    9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
    10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
    11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/4/2015)... AUSTIN, Texas , Sept. 4, 2015  Luminex ... will present at the Morgan Stanley Global Healthcare Conference ... the Grand Hyatt Hotel in New York ... begin at 11:40 a.m. Eastern time on Friday, September ... be accessed at Luminex Corporation,s website at http://www.luminexcorp.com ...
    (Date:9/4/2015)... PUNE, India , September 4, 2015 ... "Apheresis Market by Application (Plasmapheresis, Plateletpheresis, Erythrocytapheresis, Leukapheresis, and ... by Technology and by Product - Global Forecast to ... expected to reach USD 2.5 Billion by 2020, growing ... from 2015 to 2020. Browse 139 ...
    (Date:9/4/2015)... Oramed Pharmaceuticals Inc. (NASDAQ: ... focused on the development of oral drug delivery systems, ... upcoming Rodman & Renshaw 17 th Annual Global ... New York City .  Dr. Michael ... overview on September 9, 2015. Presentation ...
    Breaking Medicine Technology:Luminex Corporation To Present At The Morgan Stanley Global Healthcare Conference 2Apheresis Market Worth 2.5 Billion USD by 2020 2Apheresis Market Worth 2.5 Billion USD by 2020 3Apheresis Market Worth 2.5 Billion USD by 2020 4Apheresis Market Worth 2.5 Billion USD by 2020 5Oramed to Present at the Rodman & Renshaw Global Investment Conference 2Oramed to Present at the Rodman & Renshaw Global Investment Conference 3
    ... Pharmaceuticals, Inc., a private, specialty pharmaceutical company focused on ... nervous system (CNS) diseases and trauma, announced today that ... treatment of acute migraine attacks, from the specialist healthcare ... the precise cause of migraines is not fully understood, ...
    ... Cohera Medical, a rapidly growing medical device company, announced today ... 50 Awards. Cohera Medical was recognized as the 2011 Life ... Executive Officer, Patrick Daly, was named Pittsburgh CEO of the ... by the Pittsburgh Technology Council as a company that is ...
    Cached Medicine Technology:Ariel Pharmaceuticals, Inc. Acquires Novel Compound for Acute Migraine 2Ariel Pharmaceuticals, Inc. Acquires Novel Compound for Acute Migraine 3Cohera Medical and CEO Receive Pittsburgh Tech 50 Awards 2Cohera Medical and CEO Receive Pittsburgh Tech 50 Awards 3
    (Date:9/4/2015)... ... September 04, 2015 , ... Scalability Experts (SE) announced that ... at this year’s Microsoft Worldwide Partner Conference that was held in Orlando, Florida. ... Winner for Data Platform services, the 2015 HP and Microsoft “Outstanding Frontline Partner” ...
    (Date:9/4/2015)... Francisco, CA (PRWEB) , ... September 04, 2015 ... ... Amini, announces that CEREC technology is now available at CitiDent. CEREC is a ... machinery. In addition to saving time for patients by eliminating the need for ...
    (Date:9/4/2015)... ... 2015 , ... Mike Day, a former Navy SEAL who was shot 27 ... Championships in Kona on October 10th. , Mike is running the race to raise ... and the cutting-edge treatments that restore their quality of life. More than ...
    (Date:9/4/2015)... ... September 04, 2015 , ... ... of personal humidifying medical devices, announced its only mission and research focus: Water ... Research Founder Sharon Kleyne, body water evaporation is becoming dangerously accelerated. As a ...
    (Date:9/4/2015)... ... September 04, 2015 , ... The conference program for ... Florida October 9-10, 2015 at the Diplomat Resort & Spa has been announced ... and researchers at the top of their field and will be presenting sessions ...
    Breaking Medicine News(10 mins):Health News:Scalability Experts is Awarded Three Separate 2015 “Partner of the Year” Awards at Microsoft’s Worldwide Partner Conference 2Health News:Scalability Experts is Awarded Three Separate 2015 “Partner of the Year” Awards at Microsoft’s Worldwide Partner Conference 3Health News:Scalability Experts is Awarded Three Separate 2015 “Partner of the Year” Awards at Microsoft’s Worldwide Partner Conference 4Health News:San Francisco Dentist, Dr. Ben Amini, is Now Offering CEREC Technology at CitiDent 2Health News:Navy SEAL Shot 27 Times Competes in Ironman World Championship in Kona to Raise Money for Veteran's Suffering from TBI and PTSD 2Health News:Bio-Logic Aqua® Research Announces Water Life Science and Body Water Evaporation as Research Focus and Mission 2Health News:Bio-Logic Aqua® Research Announces Water Life Science and Body Water Evaporation as Research Focus and Mission 3Health News:Integrative Healthcare Symposium Focus On: The Microbiome Conference Program Announced 2
    ... Awards go to Henry Ford Health System, MSU, ... 2008 Five Michigan researchers whose,work has helped ... research dollars totaling $50,000 through Blue Cross Blue ... Awards., The researchers are from Henry Ford ...
    ... 2008 Protection against,vaccine-preventable diseases is not only ... clinicians aware of the importance of,complete and timely ... Practice has published a supplement to the April ... your community adequately,protected?, Based on a recently ...
    ... Characterization of Dry-Patch ... Vaccine -, ... announced it will receive a,cost-reimbursement grant for up to $943,856 from the ... a,patch-based version of the anthrax vaccine., Under the 1-year grant, Iomai ...
    ... Just Plain Fraudulent Asks Top Acupuncture Physician, ... when you,thought it was safe to get acupuncture ... the right to be shamelessly under qualified. This,time ... ordinary to "cure" asthma,ADD, hot flashes, post-stroke injury, ...
    ... Two Hospitals in the System - Sentara Heart Hospital ... Beach General Hospital ... - Novadaq(R) Technologies Inc.,(TSX: NDQ), a developer of real-time ... today announced that Sentara Heart,Hospital(R) in Norfolk, Virginia and ...
    ... TAMPA, Fla., April 8, 2008 A Tampa-area ... medical reporting,systems that allows physicians to gain approval ... with patients as a result., As medical ... -- making patients wait longer for procedures and,giving ...
    Cached Medicine News:Health News:Researchers Able to Continue their Work to Help Patients Thanks to McDevitt Excellence in Research Awards from Blue Cross Blue Shield of Michigan Foundation 2Health News:Adults Need Protection Against Vaccine-Preventable Diseases, Too 2Health News:Iomai Wins Department of Defense Grant to Develop a Stable, Patch-Based Anthrax Vaccine 2Health News:Iomai Wins Department of Defense Grant to Develop a Stable, Patch-Based Anthrax Vaccine 3Health News:Iomai Wins Department of Defense Grant to Develop a Stable, Patch-Based Anthrax Vaccine 4Health News:SNAP! CRACKLE! POP! Untrained Chiropractors Doing Acupuncture! 2Health News:Virginia's largest Cardiac Surgery program adopts SPY as standard of care 2Health News:Virginia's largest Cardiac Surgery program adopts SPY as standard of care 3Health News:Virginia's largest Cardiac Surgery program adopts SPY as standard of care 4
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    ... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
    ... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
    ... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
    Medicine Products: